Catalyst
Slingshot members are tracking this event:
Alder (ALDR) to Initiate Phase III PROMISE 2 Study Evaluating ALD403 in Frequent Episodic Migraines in H2 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALDR |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 28, 2016
Occurred Source:
http://investor.alderbio.com/releasedetail.cfm?ReleaseID=1001091
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase Iii Trial, Promise 2, Ald403, Frequent Episodic Migraines, H2 2016
